Introduction
Modified Vaccinia Virus Ankara (MVA) is a double-stranded DNA poxvirus derived from a Turkish smallpox vaccine strain through more than 570 passages in primary chicken embryo fibroblasts (1) .
Consequently, it has lost nearly 30 Kb of genomic information and is unable to complete its replication cycle in most mammalian cells. MVA has several features that render it a good vector for targeted immunotherapy of cancer: (i) an excellent safety profile in humans (1); (ii) a large amount of foreign DNA (up to 20 Kb) can be integrated into the MVA genome without loss of infectivity; (iii) viral DNA remains in the cytoplasm and, therefore, gene expression is cytoplasmic; (iv) MVA has the ability to induce both humoral and cellular responses against the encoded foreign antigens (2, 3) .
Based on promising preclinical results, clinical trials for cancer immunotherapy have been and currently are being conducted using recombinant MVA that is injected subcutaneously (s.c.) (1) .
Nevertheless, similar to most cancer immunotherapies, translation of preclinical efficacy to clinical benefit has remained below expectations (4) . Generation of robust cellular immunity to tumorassociated antigens requires the induced tumor-specific T cells to traffic to and enter the tumors (5) . Tcell infiltration is associated with patient survival in many cancers (6) (7) (8) , and it is now accepted that one of the major challenges of immunotherapy is to target T cells to the tumors (9) . In this context, most preclinical therapeutic cancer models, which are based on ectopic (s.c.) implantation of tumor cell lines from various tumor types, are poor representative of the clinical situation. One of the differences is the tumor microenvironment at the anatomical site of injection resulting from the implanted tumor cells. For example, the implantation of colorectal adenocarcinoma cells under the skin would not recreate a tumor microenvironment reflecting that of spontaneous colon cancer. In addition, there is now evidence to suggest that the immunization route influences the subsequent migratory capacity of primed, antigen-specific T cells (10) (11) (12) . Hence, s.c. or intramuscular (i.m.)
immunizations of immunotherapeutic drugs may not be optimal for directing the primed, antigenspecific T cells to visceral organ tumor tissue.
To address these issues, we used a BALB/c orthotopic renal carcinoma (RenCa) model based on subcapsular kidney implantation of RenCa cells expressing the human xeno-antigen mucin 1 (MUC1; RenCa-Muc1). Renal cell carcinoma (RCC) accounts for nearly 3% of adult cancers and is thus the 10 th most common malignancy in developed countries (13) . Furthermore, the MUC1 antigen is detected in more than 80% of human primary renal carcinoma (14) . This pathology is characterized by the absence of early warning signs and resistance to radiotherapy and chemotherapy. As a result, one third of RCC patients display distant metastasis at the time of diagnosis, and metastatic relapse occurs in 40% of patients after nephrectomy. These patients face a poor prognosis and have few therapeutic options (15) . 
Material and Methods

Mice and cell line
Six-week old BALB/c mice (Charles River Laboratories) were housed in a pathogen-free animal facility and acclimatized for one week. Taconic) by real time PCR, most recently in August of 2013.
Constructs
MVA-MUC1 plasmid was generated by introducing a modified sequence of the human MUC1 cDNA (NCBI Nucleotide database # NM_002456.5) under the control of the pH5R promoter into the natural deletion II of the parental virus MVA-TGN33.1 (17) . The "empty" MVA-TGN33.1 vector without any inserted transgene is designated control MVA.
Orthotopic Renal Carcinoma model
Mice were anesthetized with isoflurane and a lateral incision was made in the left flank of each mouse. 
Antibodies and flow cytometry
To characterize the infiltration of renal tumors by immune cells and to assay gene reporter expression by APCs, lymphoid and non-lymphoid organs were cut into small pieces, transferred into PBS- 
Immunohistochemistry (IHC)
Mouse formalin-fixed paraffin-embedded tissue sections were deparaffinized and rehydrated. Epitopes were retrieved by boiling in a 10 mM Citrate Buffer, pH 6. Sections were saturated with 3% H 2 O 2 and 10% goat serum to eliminate endogenous peroxidase activity and non-specific staining, respectively, before incubation for 90 minutes at room temperature with antibody against CD3 (Dako). Envision system (HRP-conjugated polymer coupled to secondary antibody (Dako) and TSA-Cy3 (Perkin Elmer) was used for signal amplification. Finally, sections were counterstained with 0.5 mg/mL DAPI (Hoechst 33258, B-2883, Sigma) and mounted in Mowiol (Calbiochem). Images were acquired with an optical microscope 90i (Nikon) equipped with 40x objective and epifluorescence. Signal was quantified on section scans (Nanozoomer, Hamamatsu) using the Calopix software (TRIBVN). The blue pixels defined the tumor section surface while the red pixels corresponding to the immunostained cell surface. The percentages of positive cells were calculated as (red pixels/blue pixels) x100. and analyzed with ImmunoSpot® software.
ELISpot assay
Gene expression analysis
Tumor samples were collected in RNeasy lysis buffer (Qiagen). After tissue dissociation, RNA was extracted using the Qiagen RNeasy Mini Kit. cDNA was reverse transcribed from RNA and genomic 
Statistical analysis
Statistical analyses were performed using Prism (Graphpad software). Statistical significance of survival was evaluated by the Log Rank assay. For multiple group comparisons, non-parametric Kruskal-Wallis and Dunns multiple-comparison tests were used. For ELISpot data, statistical significance was evaluated with the DFR(eq) script (20) . Differences were considered statistically significant when p<0.05.
on October Of note, i.v. treatment by ODN1826 alone of tumor-bearing animals significantly increased the number of Treg lymphocytes in kidney-bearing tumors (Fig. 3G, p<0 .01). Consistent with these results, results from IHC analyses indicated that tumor cores from MVA-MUC1-treated mice were more infiltrated with CD3 + lymphocytes than were those treated with ODN1826 alone (Fig. 3H, I ).
This infiltration was similar in invasive margins of tumors (Suppl. 
Importance of CD8 + lymphocytes
The presence of CD3 + CD8 + T lymphocytes in kidneys after i. 5C ). The impact of the route of administration on the MUC1-specific T-cell response was also explored. We compared the immune response to MUC1 after s.c. versus i.v. injections of MVA-MUC1. Only one i.v. injection of MVA-MUC1 was sufficient to induce a detectable and significant immune response to MUC1 as determined by IFN ELISpot assay (Fig. 5D, left panel) . In contrast, 2 injections were necessary to observe a significant response via the s.c. route (Fig. 5D right panel) .
Surprisingly, ODN1826 addition to the respective immunization schemes diminished to background levels the specific cellular immune response to MUC1 by splenic lymphocytes.
Immunophenotyping of kidney-infiltrating lymphocytes
We next investigated T-cell memory phenotype as well as patterns of chemokine receptor and immune checkpoint markers expression of tumor-bearing kidney-infiltrating CD8 + and CD4 + T cells.
Splenocytes from matching animals were included for comparison. 
CD4
+ T lymphocytes (22) . In contrast kidney-infiltrating T lymphocytes were mostly of the CD45RB low memory phenotype (Fig. 6A) . An up-regulation of T-lymphocyte receptors specific for chemokines expressed in target tissues following antigen encounter and T-cell proliferation has been described (23) . In particular CCR1, CCR2, CCR3 and CCR5 are necessary to enable appropriate redistribution of activated T cells (23) .
Consistent with this, a low proportion of CD8 + and CD4 + splenocytes expressed these chemokine receptors whereas, in any analyzed group, most tumor-bearing kidney-infiltrating T lymphocytes were positive for these receptors (suppl Fig. 3 ). In contrast, CXCR3 expression was detected on the surface of approximately 40% of CD3 + CD8 + splenocytes whereas only about 10% of CD3 + CD8 + lymphocytes from kidneys expressed this receptor (Fig. 6B ). Intravenous treatment with MVA-MUC1 significantly increased to about 30% the proportion of CD3 + CD8 + lymphocytes expressing CXCR3 (Fig. 6B) . The proportion of CD3 + CD4 + splenocytes and kidney lymphocytes expressing CXCR3 was also low (5-25%). However a higher proportion of kidney-infiltrating CD4 + lymphocytes from MVA-MUC1-treated animals expressed CXCR3 ( 
collateral tissue damage during an immune response. Tumors divert this physiological process to escape destruction by cytotoxic T lymphocytes. Hence, we monitored the level of expression of PD-1, Tim3, and LAG3 in our model. Expression of PD-1 on tumor-bearing kidney-infiltrating T lymphocytes was markedly increased upon injection of MVA-MUC1 and/or ODN1826 (Fig. 6C upper   panels, Fig. 6D 
Analysis of tumor-bearing kidney gene expression
To gain further insight into immune/inflammatory activity in tumors following treatment we analyzed 84 genes involved in inflammation using qRT-PCR. When compared to normal kidneys expression of 
Discussion
We analyzed the impact of the route of injection on the immunotherapeutic activity of MVA-MUC1 in an orthotopic model of renal carcinoma, and report that the i.v. route is superior to the classical s.c.
route.
Consistent with work from others in this model (38, 39) It is recognized that T cells generated from antigen-specific immunotherapy must traffic to and infiltrate tumor tissue for optimal efficacy. T-cell infiltration in tumors has been associated with favorable outcome for patients in some of the most prevailing cancers (6) (7) (8) . In this study we show that, when compared to s.c. injection, i.v. injection of MVA-MUC1 induces massive infiltration of
CD8
+ lymphocytes in peripheral organs as well as in kidney tumors. This observation is neither linked to the presence of tumor nor to the antigenic specificity encoded by MVA. Dissemination of effector T cells to non-lymphoid tissues during infection has been characterized in various models of infection and it is thought to reflect a general mechanism of organ protection (41) . We observed that only CD8 + T lymphocytes infiltrated organs following i.v. injection of MVA-MUC1 suggesting that a defined molecular mechanism rather than a passive diffusion is responsible of this phenomenon. Furthermore, the primary site of antigen encounter imprints the generated antigen-specific T cells with matching migratory capacities (10) (11) (12) . Hence, the observations described in this paper are likely to explain why has been shown to increase survival of patients with metastatic non-small cell lung cancer (49) . In this phase 2B trial, TG4010 was injected into patients via the s.c. route in addition to chemotherapeutic standard of care. In light of our preclinical results, patients could benefit from i.v. injection of TG4010. It is now routine to produce constant clinical grade batches of recombinant pox viruses.
These replication competent viruses are injected intravenously and intra-hepatically in clinical studies (50) . This, combined with the good safety record of MVA in the clinic (1) makes it reasonable to consider that, after appreciation of the benefit/risk ratio, a MVA vector may receive approval for i.v.
injection in humans for advanced cancer therapy.
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